Nuclear factor kappa B activation and regulation of cyclooxygenase type-2 expression in human amnion mesenchymal cells by interleukin-1beta.
Interleukin-1beta (IL-1beta) has been shown in numerous studies to increase prostaglandin (PG) output by up-regulating the expression of cyclooxygenase-2 (COX-2), a rate-limiting enzyme in PG synthesis. In this study, we investigated the possible role of the nuclear factor kappa B (NFkappaB) in IL-1beta signaling, leading to the expression of COX-2 in human amnion cell culture. Fetal amnion was obtained following vaginal delivery and digested with collagenase, and the subepithelial (mesenchymal) cells were isolated. Cultures were characterized with antisera to keratin (epithelial cells) and vimentin (mesenchymal cells). Confluent cells were stimulated with human recombinant IL-1beta, and activation of NFkappaB was assessed by measuring changes in the inhibitory protein IkappaB (total IkappaB and phosphorylated IkappaB) using Western blot analysis as well as by nuclear binding of NFkappaB using an electrophoretic mobility shift assay. COX-2 protein levels were determined by Western blot analysis. After 5 min of stimulation with IL-1beta, phosphorylated IkappaB began to appear, 90% of which was degraded within 15 min. This was temporally associated with decreased total IkappaB and increased nuclear NFkappaB DNA-binding activity. In the IL-1beta-treated group, COX-2 protein began to increase after 6 h; this response was time-dependent, with a significant increase until 24 h after IL-1beta stimulation. When NFkappaB translocation was blocked by using SN50 (a cell-permeable inhibitory peptide of NFkappaB translocation), the synthesis of COX-2 protein was inhibited. These results suggest that NFkappaB is involved in the IL-1beta-induced COX-2 expression in the mesenchymal cells of human amnion.
Yan
Xiaojuan
X
Division of Maternal-Fetal Medicine and Reproductive Biology Unit, Department of Obstetrics and Gynecology, University of Ottawa, Ottawa Health Research Institute, Ottawa, Ontario, Canada K1H 8L6.
Wu Xiao
Chao
C
Sun
Meihua
M
Tsang
Benjamin K
BK
Gibb
William
W
D000650:Amnion / Q000201:enzymology*; D015153:Blotting, Western; D002478:Cells, Cultured; D051546:Cyclooxygenase 2; D004247:DNA / Q000378:metabolism; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism / Q000494:pharmacology*; D007527:Isoenzymes / Q000235:genetics*; D007633:Keratins / Q000032:analysis; D007700:Kinetics; D008565:Membrane Proteins; D008648:Mesoderm / Q000201:enzymology; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000502:physiology*; D010455:Peptides / Q000494:pharmacology; D010766:Phosphorylation; D011247:Pregnancy; D011451:Prostaglandin-Endoperoxide Synthases / Q000235:genetics*; D011994:Recombinant Proteins / Q000494:pharmacology; D015398:Signal Transduction; D014746:Vimentin / Q000032:analysis
D007375:Interleukin-1; D007527:Isoenzymes; D008565:Membrane Proteins; D016328:NF-kappa B; D010455:Peptides; D011994:Recombinant Proteins; C118258:SN50 peptide; D014746:Vimentin; D007633:Keratins; D004247:DNA; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases